| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| T Sugiura, S Kondo, S Kishimoto, T Miyashita, S Nakane, T Kodaka, Y Suhara, H Takayama, K Wak. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. The Journal of biological chemistry. vol 275. issue 1. 2000-01-31. PMID:10617657. |
we examined the effect of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, on the intracellular free ca(2+) concentrations in hl-60 cells that express the cannabinoid cb2 receptor. |
2000-01-31 |
2023-08-12 |
Not clear |
| D Melck, L De Petrocellis, P Orlando, T Bisogno, C Laezza, M Bifulco, V Di Marz. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. vol 141. issue 1. 2000-01-13. PMID:10614630. |
beta-ngf-induced hbcc proliferation was potently inhibited (ic50 = 50-600 nm) by the synthetic cannabinoid hu-210, 2-ag, anandamide, and its metabolically stable analogs, but not by the anandamide congener, palmitoylethanolamide, or the selective agonist of cb2 cannabinoid receptors, bml-190. |
2000-01-13 |
2023-08-12 |
human |
| D Melck, L De Petrocellis, P Orlando, T Bisogno, C Laezza, M Bifulco, V Di Marz. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. vol 141. issue 1. 2000-01-13. PMID:10614630. |
hbccs and du-145 cells were shown to contain 1) transcripts for cb1 and, to a lesser extent, cb2 cannabinoid receptors, 2) specific binding sites for [3h]sr141716a that could be displaced by anandamide, and 3) a cb1 receptor-immunoreactive protein. |
2000-01-13 |
2023-08-12 |
human |
| Z Járai, J A Wagner, K Varga, K D Lake, D R Compton, B R Martin, A M Zimmer, T I Bonner, N E Buckley, E Mezey, R K Razdan, A Zimmer, G Kuno. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 24. 2000-01-06. PMID:10570211. |
two cannabinoid receptors, cb1 and cb2, have been cloned, and studies with the selective cb1 receptor antagonist sr141716a have implicated peripherally located cb1 receptors in the hypotensive action of cannabinoids. |
2000-01-06 |
2023-08-12 |
mouse |
| Z Járai, J A Wagner, K Varga, K D Lake, D R Compton, B R Martin, A M Zimmer, T I Bonner, N E Buckley, E Mezey, R K Razdan, A Zimmer, G Kuno. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 24. 2000-01-06. PMID:10570211. |
here we show that "abnormal cannabidiol" (abn-cbd) is a neurobehaviorally inactive cannabinoid that does not bind to cb1 receptors, yet causes sr141716a-sensitive hypotension and mesenteric vasodilation in wild-type mice and in mice lacking cb1 receptors or both cb1 and cb2 receptors. |
2000-01-06 |
2023-08-12 |
mouse |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
the discovery of this 'endogenous cannabinoid system' has led to the development of selective cb1 and cb2 receptor ligands and fueled renewed interest in the clinical potential of cannabinoids. |
2000-01-05 |
2023-08-12 |
Not clear |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
so too may cb2 receptor ligands and drugs that activate cannabinoid receptors indirectly by augmenting endocannabinoid levels at cannabinoid receptors. |
2000-01-05 |
2023-08-12 |
Not clear |
| R Mechoula. Recent advantages in cannabinoid research. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575284. |
in the last decade it was established that delta9-thc acts through specific receptors - cb1 and cb2 - and mimics the physiological activity of endogenous cannabinoids of two types, the best known representatives being arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-ag). |
2000-01-05 |
2023-08-12 |
Not clear |
| R A Ross, T M Gibson, L A Stevenson, B Saha, P Crocker, R K Razdan, R G Pertwe. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. British journal of pharmacology. vol 128. issue 3. 1999-12-22. PMID:10516656. |
o-1184, o-1238 and o-584 displaced [3h]-cp55940 from specific binding sites on chinese hamster ovary (cho) cell membranes expressing cb1 or cb2 cannabinoid receptors, with pki values of 8.28 to 8.45 (cb1) and 8.03 to 8.13 (cb2). |
1999-12-22 |
2023-08-12 |
mouse |
| A C Herring, N E Kaminsk. Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. The Journal of pharmacology and experimental therapeutics. vol 291. issue 3. 1999-12-20. PMID:10565837. |
cannabinol (cbn), an immunosuppressive cannabinoid and ligand for the peripheral cannabinoid receptor cb2, inhibits the camp signaling cascade in forskolin-stimulated thymocytes. |
1999-12-20 |
2023-08-12 |
Not clear |
| B Y Ho, Y Uezono, S Takada, I Takase, F Izum. Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors & channels. vol 6. issue 5. 1999-12-13. PMID:10551268. |
coupling of the expressed cannabinoid cb1 and cb2 receptors to phospholipase c and g protein-coupled inwardly rectifying k+ channels. |
1999-12-13 |
2023-08-12 |
xenopus_laevis |
| B Y Ho, Y Uezono, S Takada, I Takase, F Izum. Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors & channels. vol 6. issue 5. 1999-12-13. PMID:10551268. |
signaling of the cannabinoid cb1 and cb2 receptors through phospholipase c (plc) and g protein-coupled inwardly rectifying k+ channels (girk) was studied after their expression in cos7 cells and xenopus oocytes. |
1999-12-13 |
2023-08-12 |
xenopus_laevis |
| A A Izzo, N Mascolo, R Capasso, M P Germanò, R De Pasquale, F Capass. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn-Schmiedeberg's archives of pharmacology. vol 360. issue 2. 1999-11-08. PMID:10494894. |
we have studied the effect of win 55,212-2 (a psychoactive cannabinoid agonist), cannabinol (a nonpsychoactive cannabinoid agonist), sr141716a, a cannabinoid cb1 antagonist, and sr144528, a cannabinoid cb2 antagonist, on gastric emptying in the rat. |
1999-11-08 |
2023-08-12 |
rat |
| V Chapma. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. British journal of pharmacology. vol 127. issue 8. 1999-10-21. PMID:10482905. |
the effect of spinal administration of the selective cannabinoid cb1 receptor antagonist, sr141716a, and the selective cb2 receptor antagonist, sr144528, on innocuous versus noxious evoked responses of dorsal horn neurones in the spinal cord of the anaesthetized rat was investigated. |
1999-10-21 |
2023-08-12 |
rat |
| V Chapma. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. British journal of pharmacology. vol 127. issue 8. 1999-10-21. PMID:10482905. |
the results of this study provide evidence that tonic cannabinoid cb1 receptor activation, but not cb2 receptor activation, attenuates acute nociceptive transmission, at the level of the spinal cord. |
1999-10-21 |
2023-08-12 |
rat |
| A G Hohmann, M Herkenha. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. vol 92. issue 4. 1999-10-08. PMID:10426476. |
the present study was conducted to evaluate axonal flow of cannabinoid receptors from the dorsal root ganglion to the periphery and to identify the putative involvement of cb1 and/or cb2 receptor subtypes. |
1999-10-08 |
2023-08-12 |
rat |
| P H Reggi. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges. Current medicinal chemistry. vol 6. issue 8. 1999-10-07. PMID:10469885. |
ligand-ligand and ligand-receptor approaches to modeling the cannabinoid cb1 and cb2 receptors: achievements and challenges. |
1999-10-07 |
2023-08-12 |
Not clear |
| P H Reggi. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges. Current medicinal chemistry. vol 6. issue 8. 1999-10-07. PMID:10469885. |
the cannabinoid cb1 and cb2 receptors belong to the super family of g protein-coupled receptors. |
1999-10-07 |
2023-08-12 |
Not clear |
| J W Huffma. Cannabimimetic indoles, pyrroles and indenes. Current medicinal chemistry. vol 6. issue 8. 1999-10-07. PMID:10469887. |
this led to the discovery that 1-propyl-3-(1-naphthoyl)indole is a selective ligand for the peripheral cannabinoid (cb2) receptor, and to the development of a series of cannabimimetic pyrroles. |
1999-10-07 |
2023-08-12 |
Not clear |
| F Barth, M Rinaldi-Carmon. The development of cannabinoid antagonists. Current medicinal chemistry. vol 6. issue 8. 1999-10-07. PMID:10469889. |
the discovery of two distinct cannabinoid receptors (cb1 and cb2) in the early 1990's has revived the research on cannabinoid antagonists. |
1999-10-07 |
2023-08-12 |
Not clear |